keyword
MENU ▼
Read by QxMD icon Read
search

R-chop

keyword
https://www.readbyqxmd.com/read/29675104/prognostic-value-of-bone-marrow-fdg-uptake-pattern-of-pet-ct-in-newly-diagnosed-diffuse-large-b-cell-lymphoma
#1
Yumei Chen, Mingge Zhou, Jianjun Liu, Gang Huang
Purpose: The value of 18 F-fluorodeoxyglucose positron emission tomography /computed tomography (18 F-FDG PET/CT) in assessing bone marrow involvement (BMI) of lymphoma remains controversial. The present study aims to evaluate the prognostic meaning of bone marrow FDG uptake pattern in PET/CT of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. Materials and Methods: 193 newly diagnosed DLBCL patients were retrospectively analyzed. All patients received 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29674626/prognostic-significances-of-overexpression-myc-and-or-bcl2-in-r-chop-treated-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis
#2
Lu Li, Yanyan Li, Ximei Que, Xue Gao, Qian Gao, Mingxing Yu, Kaili Ma, Yanfeng Xi, Tong Wang
Numerous studies have investigated the prognostic values of MYC and/or BCL2 protein overexpression in diffuse large B-cell lymphoma (DLBCL). However, the results still demonstrate discrepancies among different studies. We aimed to do a systematic review and meta-analysis on the relationships between overexpression MYC and/or BCL2 and DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). This study followed the guidelines of PRISMA and Cochrane handbook. The hazard ratios (HRs) for overall survival (OS) were pooled to estimate the main effect size...
April 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29666081/mantle-cell-lymphoma-presenting-as-bilateral-adrenal-huge-masses
#3
Abtin Doroudinia, Mehrdad Bakhshayesh Karam, Mostafa Ranjbar, Arash Nikmanesh, Payam Mehrian
We present a middle-aged woman complaining of weakness, lethargy and weight loss for 6 months. Positron emission tomography (PET)/CT scan revealed huge bilateral adrenal masses with intense 18F-fluorodeoxyglucose avidity. Biopsy and immunohistochemical staining were compatible with mantle cell lymphoma (MCL). The patient received six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) followed by four cycles of intrathechal methotrexate chemotherapy. Bone marrow aspiration biopsy was performed for initial staging and also before bone marrow transplantation...
April 17, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29659676/methodology-of-clinical-trials-evaluating-the-incorporation-of-new-drugs-in-the-first-line-treatment-of-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-a-critical-review
#4
G Iacoboni, E Zucca, M Ghielmini, A Stathis
Purpose: The first line treatment of diffuse large B-cell lymphoma (DLBCL) is the combination of rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, curing approximately 60% of patients. Many clinical trials have been performed over the last 10 years trying to improve the results of this treatment, but the appropriateness of their planning strategies could be rediscussed. Patients and Methods: Reports of phase 3 trials evaluating the addition of molecularly targeted agents (MTA) or new monoclonal antibodies to the classic R-CHOP backbone in first-line induction or maintenance treatment were reviewed...
April 5, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29658143/which-very-elderly-diffuse-large-b-cell-lymphoma-patients-can-benefit-from-curative-treatment-a-multicenter-retrospective-analysis-by-the-spanish-geltamo-group
#5
Emilia Pardal, Eva Díez Baeza, Queralt Salas, Tomás García, Juan M Sancho, Encarna Monzón, José M Moraleda, Raúl Córdoba, Fátima de la Cruz, José A Queizán, María J Rodríguez, Belén Navarro, José A Hernández, Rosana Díez, María Vahi, María C Viguria, Miguel Canales, María J Peñarrubia, Tomás J González-López, Santiago Montes-Moreno, Eva González-Barca, Dolores Caballero, Alejandro Martín
The means of optimally managing very elderly patients with diffuse large B-cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80-100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated in 19 hospitals from the GELTAMO group. Primary objective was to analyze the influence of the type of treatment and comorbidity scales on progression-free survival (PFS) and overall survival (OS). 163 patients (63%) were treated with chemotherapy that included anthracyclines and/or rituximab, whereas 15% received no chemotherapeutic treatment...
April 15, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29629728/the-impact-of-drug-metabolism-gene-polymorphisms-on-therapeutic-response-and-survival-in-diffuse-large-b-cell-lymphoma-patients
#6
Ildikó Pál, Árpád Illés, Lajos Gergely, Tibor Pál, Zita Radnay, Zoltán Szekanecz, Erika Zilahi, László Váróczy
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of all non-Hodgkin lymphomas (NHL) and 80% of agressive lymphomas. Besides the traditional International Prognostic Index (IPI), some other factors may also influence the prognosis of DLBCL patients. OBJECTIVES: To study how the genetic polymorphisms in the metabolic pathway influence the event-free and overall survivals and therapeutic responses in DLBCL. METHODS: The study was comprised of 51 patients (32 men, 19 women)...
April 2018: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/29616868/frontline-treatment-of-diffuse-large-b-cell-lymphoma-in-elderly-a-systematic-review-of-clinical-trials-in-post-rituximab-era
#7
Sara Beygi, Santhosh Sadashiv, James B Reilly, Cyrus Khan, John Lister
Treatment of diffuse large B cell lymphoma (DLBCL) remains challenging in elderly population and systematic reviews are lacking in this area. Medline and Cochrane Register of Controlled Trials in addition to conference proceedings were searched for therapeutic clinical trials on frontline treatment of DLBCL in adults ≥60 in post-rituximab era. Forty-one out of 713 reviewed papers met our inclusion criteria. Six cycles of rituximab, cyclophosphamide, vincristine, prednisone (R-CHOP) administered every 21 d remain the standard treatment for fit elderly, with no role for maintenance rituximab...
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29611764/lenalidomide-combined-with-r-gdp-in-a-patient-with-refractory-cd5-positive-diffuse-large-b-cell-lymphoma-a-promising-response-and-review
#8
Yaping Zhang, Xinfeng Wang, Yifei Liu, Chunfeng Sun, Wenyu Shi, Hongming Huang
CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) is associated with poor survival compared with CD5-negative DLBCL. The clinical characteristics of CD5+ DLBCL are different from both CD5-negative DLBCL and other CD5+ B cell lymphomas. There is currently no promising chemotherapy for CD5+ DLBCL. Herein, we report a 49-year-old Asian male with refractory CD5+ DLBCL. He complained of aggravated abdominal pain and weight loss. Computed tomography scan revealed abdominal masses, widespread lymphadenopathy, splenomegaly, and intussusception of the ileocecal junction with bowel wall thickening...
April 3, 2018: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29607914/-a-case-of-neurolymphomatosis-presented-as-cauda-equine-syndrome-accompanied-with-m-proteinemia
#9
Hirofumi Konishi, Yoshiharu Taguchi, Mamoru Yamamoto, Takamasa Nukui, Nobuhiro Dougu, Yuji Nakatsuji
A 63-year-old man developed a syndrome of cauda equine, with the numbness which is a left lower extremity from the left buttocks, weakness of left leg, and a dysfunction of bladder and bowel. Enhanced MRI revealed the enhancement of lower cauda equine, and a nerve conduction test revealed decreased F-wave persistency in the tibial nerve and increased F-wave latency in the peroneal nerve on the both sides. M-proteinemia was admitted and myeloma was suspected. By a biopsy of a vertebral arch, we diagnosed with diffuse large B-cell lymphoma...
March 31, 2018: Rinshō Shinkeigaku, Clinical Neurology
https://www.readbyqxmd.com/read/29603428/retrospective-analysis-of-front-line-treatment-efficacy-in-elderly-patients-with-diffuse-large-b-cell-lymphoma
#10
Chieh-Lung Cheng, Jia-Hau Liu, Sheng-Chieh Chou, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien
OBJECTIVES: To investigate the effectiveness of two chemotherapeutic regimens, bendamustine plus rituximab (BR) or reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (RD-RCHOP), in elderly patients with treatment-naïve diffuse large B-cell lymphoma. METHODS: A retrospective study was conducted to investigate the efficacy and safety of two frontline regimens, BR and RD-RCHOP in patients aged ≥ 75 years unfit for R-CHOP. RESULTS: From January 2011 to December 2015, 26 patients received BR and 34 RD-RCHOP...
March 30, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29599623/comparison-of-prognostic-indices-in-japanese-patients-with-diffuse-large-b-cell-lymphoma-in-the-yonago-area
#11
Yuzuru Hosoda, Norihiko Hino, Toru Motokura
Background: Several prognostic indices for diffuse large B-cell lymphoma (DLBCL) have been developed. Which index is appropriate for Japanese patients with DLBCL treated in real-world practice is unknown. Methods: The prognostic performances of the original international prognostic index (IPI), age-adjusted IPI, National Comprehensive Cancer Network-IPI, elderly IPI and revised IPI were compared using patients with DLBCL treated in a single institute in the Yonago area in Japan...
March 2018: Yonago Acta Medica
https://www.readbyqxmd.com/read/29578182/diffuse-large-b-cell-lymphoma-with-concurrent-hepatitis-b-virus-infection-in-the-mabthera-era-unique-clinical-features-and-worse-outcomes
#12
Xiao Yan, Miao Zhou, Zhongze Lou, Qitian Mu, Lixia Sheng, Ping Zhang, Yi Wang, Guifang Ouyang
Aim of Study: Hepatitis B virus (HBV) infection is a risk factor in diffuse large B-cell lymphoma (DLBCL); however, little is known other than the prevalence evidence. In addition, the impact of HBV infection to DLBCL remains controversial. The purpose of this study was to investigate the HBV infection status of 136 patients with DLBCL, analyze the clinical property of HBV-infected patients, and determine the effects of HBV infection to the outcomes of DLBCL patients. Materials and Methods: A retrospective analysis was performed in our center from January 2007 to December 2014...
2018: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29577608/impact-of-salvage-treatment-modalities-in-patients-with-positive-fdg-pet-ct-after-r-chop-chemotherapy-for-aggressive-b-cell-non-hodgkin-lymphoma
#13
Vicky Chin, Michael Fulham, Mark Hertzberg, Michael Jackson, Robert Lindeman, Timothy Brighton, Giselle Kidson-Gerber, Eva A Wegner, Carol Cheung, Susan MacCallum, Janet Williams, Stephen R Thompson
INTRODUCTION: To compare outcomes of different salvage treatment modalities in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who remain FDG-PET positive after R-CHOP chemotherapy. Existing data on these patients with FDG-PET primary refractory disease are limited. METHODS: Patients with diffuse large B-cell lymphoma or grade 3 follicular lymphoma were retrospectively reviewed from the Prince of Wales Hospital databases. Eligibility criteria were: age≥18 years, treated with R-CHOP, with positive post-chemotherapy FDG-PET...
March 25, 2018: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29569279/role-of-prephase-treatment-prior-to-definitive-chemotherapy-in-patients-with-diffuse-large-b-cell-lymphoma
#14
K C Lakshmaiah, Vikas Asati, K Govind Babu, D Lokanath, Linu Abraham Jacob, M C Suresh Babu, K N Lokesh, L K Rajeev, A H Rudresh, Smitha Saldanha, Deepak Koppaka, Rajesh Patidar, C S Premalata
BACKGROUND: During the treatment of diffuse large B-cell lymphoma (DLBCL) patients, treatment-related toxicities are higher in the initial phase of treatment (First cycle effect). Toxicities can be tumour lysis syndrome, deterioration in performance status, febrile neutropenia, and rarely mortality. Prephase treatment before definitive chemotherapy is used in European countries to alleviate these toxicities. METHODS: This was a non-randomized study carried out with the aim to evaluate the role of prephase treatment given prior to definitive chemotherapy in newly diagnosed DLBCL patients...
March 22, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29564988/detection-of-the-incidence-of-infections-and-acute-biochemical-changes-in-diffuses-large-b-cell-lymphoma-patients-treated-with-cyclophosphamide-doxorubicin-vincristine-and-prednisone-chop-with-and-without-rituximab
#15
Kashif Ali, Ali Akbar Sial, Mirza Tasawer Baig, Saqib Hussain Ansari, Syed Omair Adil, Tahir Sultan Shamsi
AIM AND OBJECTIVES: Acute biochemical changes, hepatotoxicity, nephrotoxicity and frequency of infections are common in diffuse large B-cell Lymphoma patients undergoing Cyclophosphamide, hydroxyrubicin, Oncovin (Vincristine) Prednisolone (CHOP) and Rituximab plus CHOP chemo cycles. Eventually, it leads to prolong hospital stay and suspending the next chemotherapy cycles. Changes in biochemical profile and immunosuppressant effects correlated with dose intensity ratio, the findings of this study will be helpful in choices for the physician to discontinue therapy or delaying treatment...
March 20, 2018: Current Drug Safety
https://www.readbyqxmd.com/read/29546569/a-case-of-duodenal-malignant-lymphoma-presenting-as-acute-pancreatitis-systemic-lupus-erythematosus-and-immunosuppressive-therapy-as-risk-factors
#16
Reiko Yamada, Takashi Sakuno, Hiroyuki Inoue, Hiroshi Miura, Toshifumi Takeuchi, Yasunori Shiono, Hiroaki Okuse, Misaki Nakamura, Masaki Katsurahara, Yasuhiko Hamada, Kyosuke Tanaka, Noriyuki Horiki, Yoshiyuki Takei
A 49-year-old man was admitted to our hospital with pancreatitis. He was diagnosed with systemic lupus erythematosus at 34 years of age and was being treated with oral tacrolimus (3 mg/day) and predonine (10 mg/day) for the past 15 months. The computed tomography (CT) scan showed the mass lesion had invaded the pancreatic head via thickening of the duodenal wall. Upper gastrointestinal endoscopy showed the all-round ulcerative lesion from the superior duodenal angle to the descending portion. Histological examination confirmed the diagnosis of diffuse large B cell lymphoma (DLBCL)...
March 15, 2018: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/29531724/fatal-cardiac-arrhythmia-caused-by-tumor-lysis-in-a-patient-with-diffuse-large-b-cell-lymphoma-upon-start-of-r-chop
#17
Nina Sørensen, Paw Jensen, Erik Clasen-Linde, Jacob Moesgaard Larsen, Tarec El-Galaly
Tumor lysis syndrome is rare in diffuse large cell lymphoma, but it is important to recognize the risk in patients with massive tumor burden and reduced kidney function. Very intense vigilance can be necessary despite adequate prophylactic measures and certain drugs may exacerbate electrolyte derangements.
March 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29504987/isolated-skeletal-muscle-recurrence-of-an-originally-nodal-diffuse-large-b-cell-lymphoma-a-case-report-and-review-of-the-literature
#18
Nikolaos Spetsieris, Nefeli Giannakopoulou, Eleni Variami, Konstantinos Zervakis, Niki Rougala, Georgios Garefalakis, Vasiliki Skarlatou, Nora-Athina Viniou, Panagiotis Diamantopoulos
RATIONALE: Diffuse large B cell lymphoma (DLBCL) is a malignancy of the B cells with extranodal primary involvement being estimated at 30% to 40% of cases. Primary skeletal muscle presentation of DLBCL is extremely rare, with an estimated incidence of about 0.5% of extranodal lymphomas, presenting mostly in the lower extremities. The possible mechanisms of muscle involvement of DLBCL include primary extranodal disease, extension from adjacent organs (such as lymph nodes) or disseminated disease...
January 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29500147/a-retrospective-study-of-double-hit-lymphomas-in-elderly-patients-aged-70-years-overall-outcomes
#19
Christie Hancock, Phillip Knouse, Imad Almanaseer, Jacob Bitran
BACKGROUND: Double-hit lymphomas (DHLs) are high-grade diffuse large B-cell lymphomas with concurrent translocations involving myc and bcl-2 and/or bcl-6. A patient with DHL often has advanced disease at presentation and typically responds poorly to standard therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). More intensive treatment regimens have been studied; however, few data are available on the outcomes in elderly patients (aged > 70 years) treated with these therapies...
April 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29477024/the-impact-of-the-neutrophil-lymphocyte-ratio-in-response-and-survival-of-patients-with-de-novo-diffuse-large-b-cell-lymphoma
#20
Brady E Beltrán, Sally Paredes, Esther Cotrina, Eduardo M Sotomayor, Jorge J Castillo
The neutrophil:lymphocyte ratio (NLR) has emerged as prognostic in patients with hematological malignancies. We aimed at evaluating the NLR as predictive for complete response (CR) and prognostic for progression-free (PFS) and overall survival (OS) in a study cohort of 121 Peruvian patients with diffuse large B-cell lymphoma (DLCBL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Patients with an NLR ≥6 (n = 28) were more likely to have a performance status ECOG ≥2 (74% vs...
February 19, 2018: Leukemia Research
keyword
keyword
12044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"